Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%
Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

At a Glance

Live Snapshot
Market Cap$357.74M
EPS0.1900
P/E Ratio55.84
Earnings Date

dmaa

Retained Earnings

Last Annual Value

-7.27M

3-Year CAGR

-2864%

5-Year CAGR

-664%

10-Year CAGR

-176%

Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Competitors Analysis of Retained Earnings

DMAA · NASDAQ
CompanyRetained Earnings
CAGR 3Y
CAGR 5Y
CAGR 10Y
-7.27M
N/AN/AN/A 
-10.88M
N/AN/AN/A
-13.59M
N/AN/AN/A
-12.99M
N/AN/AN/A
-7.93M
N/AN/AN/A
-28.75M
N/AN/AN/A
-10.00M
N/AN/AN/A
-11.71M
N/AN/AN/A
-11.71M
N/AN/AN/A
Drugs Made In America Acquisition Corp. Ordinary Shares

Drugs Made In America Acquisition Corp. Ordinary Shares Fair Value Envelope

DMAA · NASDAQ

Our analysis suggests that DMAA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $10.61, this represents a potential HIDDEN relative to our calculated worth for Drugs Made In America Acquisition Corp. Ordinary Shares.

Intrinsic Value
Current Price: $10.61